Opioids, overdose, and medication-assisted treatment (MAT)

Date Added
September 3rd, 2020
PRO Number
Pro00101654
Researcher
Tanya Saraiya

List of Studies

Keywords
Substance Use
Summary

This study proposes to collect pilot data that will inform a future grant application. We propose to complete interviews (60 min) on 25 individuals who are currently or have previously used opioids and are either currently on MAT or chose to not begin MAT. Semi-structured interviews will identify (1) what individual and treatment factors helped participants initiate MAT or, conversely, inhibited engagement in MAT, (2) what concerns they had about starting MAT, and (3) encouraging them to reflect on what additional information could have helped them initiate MAT sooner. Eligible participants will be compensated $20 for their participation in the study.

Institution
MUSC
Recruitment Contact
Tanya Saraiya
843-792-9383
saraiya@musc.edu

MPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience

Date Added
September 1st, 2020
PRO Number
Pro00102709
Researcher
Lisa McTeague

List of Studies

Keywords
Alcohol, Brain, Drug Studies, Psychiatry, Substance Use
Summary

The purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techniques that use magnetic pulses to temporarily excite specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). TBS, which is a form of TMS, will be applied over the medial prefrontal cortex, (MPFC), which has been shown to be involved with drinking patterns and alcohol consumption. This study will test whether TBS can be used as an alternative tool to reduce the desire to use alcohol and reducing the brain's response to alcohol-related pictures.

Institution
MUSC
Recruitment Contact
Charleston Alcohol Research Center
(843) 792-1222
alcoholstudy@musc.edu

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of EMB-001 in Subjects with Moderate-to-Severe Cocaine Use Disorder

Date Added
June 25th, 2020
PRO Number
Pro00101206
Researcher
Aimee McRae-Clark

List of Studies

Keywords
Substance Use
Summary

This study is looking at an investigational medication called EMB-001, which is a combination of metyrapone and oxazepam, to see if it may be an effective treatment for cocaine use disorder. Participants will undergo screening procedures to determine eligibility, and eligible participants will take either EMB-001 or placebo twice a day for 13 weeks. During this time, participants will come to the office two times a week to meet with study personnel, and they will attend a one-month follow-up visit.

Institution
MUSC
Recruitment Contact
Lisa Nunn
843-792-0476
jenkini@musc.edu

Establishing the Neurostructural and Clinical Impact of Brain Iron Dysregulation in Cocaine Use Disorder

Date Added
April 21st, 2020
PRO Number
Pro00093920
Researcher
Jens Jensen

List of Studies

Keywords
Brain, Substance Use
Summary

The purpose of this research study is to understand if high brain iron in individuals who use cocaine is related to the severity of cocaine use disorder. We will use non-invasive brain MRI to examine if high brain iron is associated with 1) abnormal brain circuits, and 2) behavioral and cognitive problems. The consists of a screening visit to determine eligibility and an MRI scanning visit.

Institution
MUSC
Recruitment Contact
Vitria Adisetiyo
843-876-2473
adisetiy@musc.edu

Targeting Parenting to Prevent HIV and Substance Use Among Trauma-Exposed Youth: A Mixed-Methods Needs Assessment

Date Added
March 16th, 2020
PRO Number
Pro00096161
Researcher
Nada Goodrum

List of Studies

Keywords
Adolescents, Alcohol, HIV / AIDS, Mental Health, Psychiatry, Sexually Transmitted Infections (STI), Substance Use
Summary

Many adolescents experience traumatic events, such as child abuse, physical or sexual assault, or witnessing violence. Teens who experience trauma are more likely to have problems with substance use and risky sexual activity. We want to understand how parents can support their teens and help keep them safe after traumatic events.

Institution
MUSC
Recruitment Contact
Nada Goodrum
843-792-8067
goodrumn@musc.edu

Alcohol Use Disorder as a risk for Alzheimer's Disease: Insights from functional connectome analysis

Date Added
February 18th, 2020
PRO Number
Pro00096201
Researcher
Jane Joseph

List of Studies

Keywords
Alcohol, Alzheimers, Dementia, Non-interventional, Substance Use
Summary

Alcohol Use Disorder (AUD) is a risk factor for Alzheimer's Disease (AD), but more research is needed to identify the potential mechanisms underlying this risk. The present study will use fMRI to examine brain network profiles in mid-life AUD. The goal is to develop techniques to assess risk for Alzheimer's Disease and related dementias. Participation includes cognitive testing and MRI scanning.

Institution
MUSC
Recruitment Contact
Laura Lohnes
843-792-7709
lohnes@musc.edu

Natural Reward Processing in Cannabis Users

Date Added
February 12th, 2020
PRO Number
Pro00096211
Researcher
Brian Sherman

List of Studies

Keywords
Drug Studies, Substance Use
Summary

The purpose of this study is to investigate natural reward processing in cannabis users. Natural reward processing refers to how a person responds to enjoyable or stimulating non-drug experiences. Two groups will participate in the study: 1) people who use cannabis, and 2) people who do not use cannabis. The study will use personalized scripted imagery which involves developing and listening to a detailed story about a personal experience. Scripted imagery has been used to investigate responses to stress and drug experiences and will be used in this study to investigate responses to naturally rewarding experiences.

Institution
MUSC
Recruitment Contact
Zoe Brasher
843-792-5695
brasherz@musc.edu

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder

Date Added
November 5th, 2019
PRO Number
Pro00091292
Researcher
Jennifer Jones

List of Studies

Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

The purpose of the study is to examine whether an investigational medication called ketamine, which comes in the form of a nasal spray, is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

Institution
MUSC
Recruitment Contact
Jennifer Jones
(843) 792-5594
jonjen@musc.edu

tDCS-Augmented Prolonged Exposure Therapy for PTSD: A Multiple Baseline Within-Subject Clinical Trial

Date Added
November 5th, 2019
PRO Number
Pro00093774
Researcher
Adam Cobb

List of Studies

Keywords
Depression, Mental Health, Military, Nervous System, Psychiatry, Stress Disorders, Substance Use
Summary

The purpose of this study is to determine the effects of a brain stimulation technique known as transcranial direct current stimulation, or tDCS, on the benefits of Prolonged Exposure therapy, or PE, which is an effective treatment for posttraumatic stress disorder, or PTSD. tDCS has been demonstrated to be safe and effective for influencing brain activity by passing a weak electrical current through the scalp. In this study, tDCS is provided in addition to PE treatment, through the National Crime Victim's Research and Treatment Center at MUSC, or the PTSD Clinical Team Clinic within the Ralph H. Johnson VA Medical Center.

Institution
MUSC
Recruitment Contact
Adam Cobb
843-792-7688
cobbad@musc.edu

Medication treatment for Opioid use disorder in expectant Mothers (MOMS): a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations

Date Added
August 27th, 2019
PRO Number
Pro00091146
Researcher
Constance Guille

List of Studies

Keywords
Obstetrics and Gynecology, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The primary purpose of this study is to compare extended-release buprenorphine (CAM2038) to buprenorphine placed under the tongue (sublingual) in pregnant women with opioid use disorder to see if CAM2038 is as effective as sublingual buprenorphine. We are looking to recruit pregnant women who are between 18-41 years old; are between 6-30 weeks pregnant and are not planning to terminate the pregnancy; have opioid use disorder, and are enrolled or are planning to enroll in outpatient buprenorphine treatment at The Medical University of South Carolina. Participation in the study would last between 13 and 21 months total with up to between about 63-102 total visits, including weekly medication check visits and research visits.

Institution
MUSC
Recruitment Contact
Savannah Lee
8437920376
leesav@musc.edu



-- OR --